Brokerage activity remained high on November 7, with major global firms including Nomura, CLSA, Morgan Stanley, HSBC, and DAM Capital releasing fresh research updates post Q2FY26 results. Here’s a summary of the key stocks and their potential upsides based on the latest calls.
| Stock | Brokerage | Call | % Upside / Downside |
|---|---|---|---|
| Cummins India | Nomura | Buy | +4.3% |
| Birlasoft | Nomura | Neutral | -6.2% |
| Zydus Lifesciences | Nomura | Buy | +22.0% |
| Aurobindo Pharma | HSBC | Buy | +15.9% |
| Aurobindo Pharma | CLSA | Outperform | +18.1% |
| UPL | HSBC | Buy | +16.6% |
| UPL | DAM Capital | Buy | +16.6% |
| Apollo Hospitals | Morgan Stanley | Overweight | +3.4% |
| MCX | Morgan Stanley | Underweight | -36.5% |
| NHPC | CLSA | High-conviction Outperform | +41.3% |
| Godrej Properties | CLSA | Outperform | +30.0% |
| Astral | CLSA | Hold | -11.0% |
| Crompton Consumer | Morgan Stanley | Equal-weight | +11.7% |
| Crompton Consumer | CLSA | Outperform | +9.9% |
| Sun Pharma | Nomura | Buy (Upgraded) | +16.3% |
| ABB India | Nomura | Reduce | -6.4% |
| Lupin | Morgan Stanley | Overweight | +6.4% |
| Lupin | Nomura | Buy | +19.3% |
Overall, brokerages turned constructive on pharma and agri-chemical stocks such as Lupin, Sun Pharma, and UPL, while staying selective on engineering counters like ABB and MCX due to margin and valuation constraints.
Disclaimer: The views and target prices mentioned are those of the respective brokerage firms. This article is based solely on the provided inputs and is intended for informational purposes only. No investment advice.
